Our Mission:
Accelerating the prevention and cure of myeloma and improving
the quality of life for patients and families
I am a...
About Multiple Myeloma
Multiple myeloma starts in the bone marrow plasma cells. It weakens the immune system and can affect many parts of the body by causing the bone marrow to create dysfunctional antibodies and plasma cells. Living with or treating this disease means making complicated decisions, and this requires searching for reliable, current information on multiple myeloma.
How Can the International Myeloma Foundation Help?
The International Myeloma Foundation (IMF) connects people to what matters most — research that pushes the field forward, education that clarifies complex topics, support tailored to individual needs, and advocacy that amplifies every voice. Patients, care partners, healthcare professionals, and researchers can access the knowledge, resources, and community they need from the IMF to navigate life with myeloma.
In this week’s blog, glean insights from the unique perspective of IMF Support Group Leader Jim Omel — a family physician diagnosed with multiple myeloma. He talks about embracing advances in MRD testing and finding hope through advocacy. READ THE BLOG.
On Thursday, July 23, Johnson & Johnson announced positive topline results from the randomized three-arm Phase 3 MonumenTAL-6 trial, evaluating Tecvayli® (teclistamab-cqyv) plus Talvey® (talquetamab-tgvs) and Talvey plus pomalidomide in adults with relapsed or refractory multiple myeloma (RRMM) who had received one to four prior lines of therapy, including an anti-CD38 antibody and lenalidomide. The two investigational arms were compared to investigator’s choice of standard of care as the third arm: elotuzumab, pomalidomide and dexamethasone (EPd); or pomalidomide, bortezomib and dexamethasone (PVd). LEARN MORE.
The Coalition to Improve Access to Cancer Care (CIACC), convened by the International Myeloma Foundation (IMF), applauds Senators Tina Smith (D-MN) and Jerry Moran (R-KS) for reintroducing the bipartisan Cancer Drug Parity Act, legislation that would ensure patients do not face higher out-of-pocket costs simply because their prescribed anticancer treatment is taken orally rather than administered intravenously. READ THE PRESS RELEASE.
An IMF Patient and Family Seminar will take place on October 2-3, 2026, in Short Hills, New Jersey. The seminar is FREE, but in-person seating is LIMITED. REGISTER NOW.
From August 18–24, 2026, intrepid cyclists — patients, care partners, and healthcare professionals — will cross Iceland’s breathtaking landscapes to raise vital funds for the International Myeloma Foundation’s mission.
